시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 빈혈 치료제 시장 보고서(2025년)
Anemia Drugs Global Market Report 2025
상품코드 : 1760455
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,290,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,091,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,893,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

빈혈 치료제 시장 규모는 향후 수 년간 강력한 성장이 전망될 예정입니다. 예측 기간의 예상 성장은 개인 맞춤형 의약품 채택 확대, 신흥 시장의 의료비 지출 증가, 빈혈 치료제에 초점을 맞춘 임상시험 증가, 전 세계 빈혈 유병률 증가, 환자 중심의 신약 개발에 대한 강조 등에 힘입은 것입니다. 이 기간의 주요 동향으로는 빈혈의 유전자 치료의 진전, 철분 보충제의 선진적 전달 시스템의 개발, 적혈구 조혈 자극제의 혁신, 빈혈을 검출하는 진단 툴의 강화, 경구 빈혈 치료제의 새로운 발전 등을 들 수 있습니다.

맞춤형 의료가 중시되게 되어 빈혈 치료제 시장의 향후 확대가 기대됩니다. 유전적 변이를 보다 정확하게 특정할 수 있게 되었습니다. 맞춤형 의료는 개인의 유전자 프로파일에 따른 치료를 가능하게 함으로써, 약효를 높이고, 부작용을 줄여 환자의 결과를 개선해, 빈혈 치료제의 개발을 지원합니다. Personalized Medicine Coalition은 미국 식품의약국(FDA)이 2023년에 희귀질환 환자를 위해 16개의 새로운 개인 맞춤형 치료법을 승인했다고 보고했습니다.

빈혈 치료제 시장의 주요 기업은 경구 HIF-PHI(저산소 유도 인자 프롤릴 히드록실라제 억제제)와 같은 혁신적인 의약품 개발에 주력하고 있으며, 보다 효과적인 빈혈 치료제를 위해 철 대사를 개선하고 적혈구 생산을 촉진하는 것을 목표로 합니다. 경구 HIF-PHI 약은 저산소 유도 인자(HIF) 경로를 제어하는 프롤릴 히드록실라제 효소를 저해합니다. GSK plc는 만성 신장병 성인 환자의 적혈구 생산을 강화하고 빈혈을 치료하는 것을 목표로 한 치료 Jesduvroq를 발표했습니다. 이 고급 빈혈 치료제는 철분 대사와 적혈구 생성을 개선하는 동시에 개인 맞춤형 치료 방법을 지원합니다. Jesduvroq은 치료 효과를 높이기 위해 철분 신진 대사를 최적화하여 만성 신장 질환 환자의 적혈구 생산을 증가시키고 빈혈을 관리하는 데 높은 효과를 나타냅니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Anemia drugs are used to treat low levels of red blood cells (RBCs) or hemoglobin in the blood. These medications enhance oxygen transport throughout the body and help alleviate fatigue by addressing the root causes of anemia, such as iron deficiency, chronic illnesses, or kidney problems.

The main categories of anemia drugs include dietary supplements and medications. Dietary supplements are oral products that provide essential nutrients like iron, folic acid, or vitamin B12 to help manage or prevent anemia. Treatment approaches consist of oral iron therapy, parenteral iron therapy, red blood cell transfusions, and other supportive care options. The different types of anemia treated include iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia, pernicious anemia, and other forms. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. The primary end-users include clinics, healthcare facilities, and home healthcare providers.

The anemia drugs market research report is one of a series of new reports from The Business Research Company that provides anemia drugs market statistics, including anemia drugs industry global market size, regional shares, competitors with an anemia drugs market share, anemia drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the anemia drugs industry. This anemia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anemia drugs market size has grown strongly in recent years. It will grow from $14.72 billion in 2024 to $15.92 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to a higher prevalence of chronic diseases, growing awareness of iron deficiency anemia, an expanding elderly population, improved healthcare access in developing regions, and increasing demand for targeted treatments.

The anemia drugs market size is expected to see strong growth in the next few years. It will grow to $21.53 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The projected growth in the forecast period is driven by greater adoption of personalized medicine, increased healthcare spending in emerging markets, a rise in clinical trials focused on anemia treatments, the growing global prevalence of anemia, and a stronger emphasis on patient-centered drug development. Key trends during this period include progress in gene therapies for anemia, development of advanced delivery systems for iron supplements, innovations in erythropoiesis-stimulating agents, enhanced diagnostic tools for detecting anemia, and new advancements in oral anemia medications.

The growing emphasis on personalized medicine is expected to drive the expansion of the anemia drugs market moving forward. Personalized medicine is a healthcare approach that customizes treatment and medical decisions based on an individual's genetic makeup, lifestyle, and environment. This increased focus is largely due to advancements in genomic sequencing, which enable more accurate identification of genetic variations linked to diseases and treatment responses. Personalized medicine supports the development of anemia drugs by allowing treatments to be tailored according to individual genetic profiles, thereby enhancing drug effectiveness and reducing adverse effects for improved patient outcomes. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases in 2023, a substantial rise from 6 approvals in 2022. Thus, the rising focus on personalized medicine is contributing to the growth of the anemia drugs market.

Key companies in the anemia drugs market are concentrating on innovative drug development, such as oral HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitors), which aim to improve iron metabolism and boost red blood cell production for more effective anemia therapies. Oral HIF-PHI medications inhibit prolyl hydroxylase enzymes that regulate the hypoxia-inducible factor (HIF) pathway. For instance, in February 2023, GSK plc, a UK-based pharmaceutical company, introduced Jesduvroq, a treatment designed to enhance red blood cell production and treat anemia in adult patients with chronic kidney disease. This advanced anemia drug improves iron metabolism and red blood cell production while supporting personalized therapy approaches. Jesduvroq is highly effective at increasing red blood cell production and managing anemia in chronic kidney disease patients by optimizing iron metabolism for better therapeutic results.

In May 2023, Akebia Therapeutics, a U.S.-based biopharmaceutical company, partnered with Medice Arzneimittel Putter GmbH & Co. KG to commercialize Vafseo for anemia treatment in Europe and Australia. Through this collaboration, Akebia Therapeutics and Medice Arzneimittel Putter aim to promote sustainable growth and improve the accessibility of Vafseo by expanding its availability and fostering innovation. Medice Arzneimittel Putter GmbH & Co. KG is a Germany-based pharmaceutical company specializing in anemia treatments and prescription medicines.

Major players in the anemia drugs market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Biocon Limited, Akebia Therapeutics Inc., Apellis Pharmaceuticals Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Covis Pharma GmbH, AdvaCare Pharma LLC, Regen Biopharma Inc., BioLineRx Ltd., Bluebird Bio Inc.

North America was the largest region in the anemia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anemia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anemia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anemia drugs market consists of sales of androgens, hydroxyurea, luspatercept and sotatercept. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anemia Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anemia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for anemia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anemia drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Anemia Drugs Market Characteristics

3. Anemia Drugs Market Trends And Strategies

4. Anemia Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Anemia Drugs Growth Analysis And Strategic Analysis Framework

6. Anemia Drugs Market Segmentation

7. Anemia Drugs Market Regional And Country Analysis

8. Asia-Pacific Anemia Drugs Market

9. China Anemia Drugs Market

10. India Anemia Drugs Market

11. Japan Anemia Drugs Market

12. Australia Anemia Drugs Market

13. Indonesia Anemia Drugs Market

14. South Korea Anemia Drugs Market

15. Western Europe Anemia Drugs Market

16. UK Anemia Drugs Market

17. Germany Anemia Drugs Market

18. France Anemia Drugs Market

19. Italy Anemia Drugs Market

20. Spain Anemia Drugs Market

21. Eastern Europe Anemia Drugs Market

22. Russia Anemia Drugs Market

23. North America Anemia Drugs Market

24. USA Anemia Drugs Market

25. Canada Anemia Drugs Market

26. South America Anemia Drugs Market

27. Brazil Anemia Drugs Market

28. Middle East Anemia Drugs Market

29. Africa Anemia Drugs Market

30. Anemia Drugs Market Competitive Landscape And Company Profiles

31. Anemia Drugs Market Other Major And Innovative Companies

32. Global Anemia Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anemia Drugs Market

34. Recent Developments In The Anemia Drugs Market

35. Anemia Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기